Mehta Kapil, Gandhi Varsha, Pathak Sen, Aggarwal Bharat B, Grover Rajesh K
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
Anticancer Res. 2014 Nov;34(11):6791-5.
Whether it is chronic myeloid leukemia, ALK-expressing malignancies, or HER2-positive breast cancer, targeted-therapies for treatment of human cancers have shown great promise. However, as they hit a single molecule expressed in neoplastic cells, their use is frequently associated with development of resistance. In cancer cells many signaling pathways operate in parallel, hence the idea of multi-targeted therapy is prevailing. The Society of Translational Cancer Research held its biennial meeting in the capital city of India, Delhi from February 6th through 9th, 2014 to discuss 'Multi-targeted Approach to Treatment of Cancer'. Over 200 scientists, clinicians, trainees, and industry representatives from different countries gathered in Vigyan Bhavan, the hotspot of Delhi for four days to talk and discuss on a variety of topics related to multi-targeted therapeutic approaches. Talks were presented by leaders in the cancer research field from various countries. It became clear from this conference that coupling multiple targeted-agents or using an agent that hits an individual target in several independent locations in the disease-causing pathway(s) may be the best approach to treat different cancers.
无论是慢性髓性白血病、表达间变性淋巴瘤激酶（ALK）的恶性肿瘤，还是人表皮生长因子受体2（HER2）阳性乳腺癌，用于治疗人类癌症的靶向疗法都已展现出巨大潜力。然而，由于这些疗法作用于肿瘤细胞中单一表达的分子，其使用常常与耐药性的产生相关。在癌细胞中，许多信号通路并行运作，因此多靶点治疗的理念盛行。转化癌症研究协会于2014年2月6日至9日在印度首都新德里召开了两年一度的会议，讨论“癌症治疗的多靶点方法”。来自不同国家的200多名科学家、临床医生、学员和行业代表齐聚新德里的热点地区维贾扬大厦，为期四天，就与多靶点治疗方法相关的各种话题进行交流和讨论。各国癌症研究领域的领军人物进行了演讲。从这次会议可以清楚地看出，联合使用多种靶向药物或使用一种能在致病途径的几个独立位置作用于单个靶点的药物，可能是治疗不同癌症的最佳方法。
